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iddle  East  respiratory  syndrome  coronavirus
MERS-CoV)  was  ﬁrst  recognized  as  a  cause  of
evere acute  respiratory  infection  in  the  King-
om of  Saudi  Arabia  in  2012.  As  of  February
, 2016,  1638  laboratory-conﬁrmed  cases  have
een reported  to  the  World  Health  Organization,
ncluding at  least  587  deaths  [1]. While  MERS-
oV has  affected  26  countries,  the  majority  of
ases have  been  reported  in  the  Middle  East  [2].Please  cite  this  article  in  press  as:  Senga  M,  et  al.  Clinic
coronavirus  (MERS-CoV).  J  Infect  Public  Health  (2016),  http
ransmission  has  most  commonly  been  associated
ith nosocomial  outbreaks  [3—7]  and  is  occa-
ionally due  to  animal-to-human  (most  commonly
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876-0341/© 2016 Published by Elsevier Limited on behalf of King Saamel-to-human)  transmission  and  sporadic  human-
o-human  transmission  in  the  community  [3,8—12].
lthough the  number  of  symptomatic  cases  result-
ng from  secondary  and  tertiary  transmission  in
uman populations  appears  to  be  limited,  little
s known  about  potential  human-to-human  spread
mong  asymptomatic  or  minimally  symptomatic
ndividuals [3,6,11,13].
pidemiology of patients
he  majority  of  MERS-CoV  infections  have  been
bserved in  adults  (98%),  with  a  slight  male  pre-
ominance (65%)  [14]. Older  adults  and  those
ith comorbidities,  such  as  diabetes,  renal  dis-al  spectrum  of  the  Middle  East  respiratory  syndrome
://dx.doi.org/10.1016/j.jiph.2016.04.008
ase, respiratory  disease,  and  immunosuppression,
ave been  more  commonly  represented  among
hose with  severe  illness  [13,14].  Younger  and
reviously  healthy  individuals  appear  more  likely
ud Bin Abdulaziz University for Health Sciences.
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to  exhibit  mild  symptoms  or  be  asymptomatic
[5,6,11,13,15,16].  The  true  incidence  of  symp-
tomatic  and  asymptomatic  MERS-CoV  cases  remains
unclear.  Mild  and  asymptomatic  cases  may  be  mis-
diagnosed,  which  can  lead  to  underreporting  and
misclassiﬁcation  of  the  disease  and  may  also  result
in a  possible  detection  bias  depending  on  the  type
of health  facility/unit  that  the  patients  seek  treat-
ment from.  Health  care  workers  appear  to  be  at  an
increased  risk  of  being  infected  with  MERS-CoV,  and
this is  likely  mediated  by  inadequate  infection  pre-
vention and  control  (IPC)  measures  and  the  ampli-
ﬁcation  of  cases  amidst  nosocomial  outbreaks.
Clinical characteristics
After  an  incubation  period  ranging  from  2 to  14
days,  the  majority  (>70%)  of  symptomatic  patients
present  with  fever,  chills,  cough,  and  dyspnea.
Approximately,  one-third  have  myalgia,  malaise,
and  gastrointestinal  symptoms  [6,17].  Among  those
with severe  illness,  the  most  prominent  clinical
manifestations  have  been  acute,  rapidly  progres-
sive viral  pneumonia  and  pneumonitis,  leading  to
hypoxic lung  injury  and  acute  respiratory  distress
syndrome  [3,4,13,17—21]. For  those  who  become
severely ill,  the  median  time  from  the  onset  of
symptoms  to  intensive  care  unit  (ICU)  admission  is
only 5  days  [14].
Approximately,  half  of  the  known  adult  symp-
tomatic patients  have  been  admitted  to  an  ICU,
with 40—70%  requiring  mechanical  ventilation
[3—5,12,13,17—28]  and  4—17%  needing  ‘rescue’
oxygenation or  ventilation  therapy  [3,17,20,29],
such as  extracorporeal  membrane  oxygenation
and high  frequency  oscillatory  or  prone  ventila-
tion [13,21,29].  Renal  replacement  therapy  was
required  in  as  many  as  70%  of  critically  ill  patients
[3,17,18,21].  However,  the  incidence  of  renal  fail-
ure may  be  over-estimated  due  to  nosocomial
outbreaks involving  patients  with  pre-existing  renal
disease [3].  In  another  hospital  outbreak  that  was
not epidemiologically  related,  renal  dysfunction
was reported  in  only  22%  of  cases  [4].  Circulatory
shock requiring  intravenous  vasoactive  medication
has been  described  in  as  many  as  92%  of  critically
ill patients  [4,21,28].
Although  not  commonly  observed,  severe  neuro-
logical syndrome  characterized  by  varying  degrees
of consciousness,  ataxia,  focal  motor  deﬁcit,  and
bilateral  hyperintense  lesions  has  been  describedPlease  cite  this  article  in  press  as:  Senga  M,  et  al.  Clinic
coronavirus  (MERS-CoV).  J  Infect  Public  Health  (2016),  http
in 3  patients  [30]. MERS-CoV  has  not  been  isolated
from the  cerebrospinal  ﬂuid  or  the  brain  tissue
of any  of  these  patients  infected  with  the  virus,
but radiological  evidence  suggests  that  MERS-CoV
t
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ssociated  vasculopathy  may  be  an  underlying
ause [30].
Both  community-  and  nosocomial-acquired  bac-
erial and  viral  co-infections  have  been  reported
n patients  with  severe  illness  and  have  been  asso-
iated with  increased  mortality  [20,24,25,31—33].
his underscores  the  importance  of  preventive
easures and  the  need  to  consider  a broad  range  of
athogens  when  treating  patients  with  either  sus-
ected or  conﬁrmed  MERS-CoV.
Liver inﬂammation,  evidenced  by  elevated
spartate aminotransferase  and  alanine  amino-
ransferase  levels,  is  common,  especially  among
hose  who  are  critically  ill  [3,17—21]. Other  labora-
ory  ﬁndings  include  lymphopenia  and  leukopenia,
s well  as  renal  injury  and  coagulopathy  in  patients
ith severe  illness  and  multi-system  organ  dysfunc-
ion [4,20,21].
Chest  computed  tomography  has  typically
evealed unilateral  or  bilateral  inﬁltrates,  ground-
lass opacities,  occasional  pleural  effusions,  and
ntralobular  thickening  consistent  with  acute  respi-
atory distress  syndrome  and  viral  pneumonitis
13,21—23].
Among  all  patients,  the  median  time  from  symp-
om onset  to  death  was  11.5  days  (ranging  from
 to  298  days)  [6,14]. The  median  length  of  stay
n the  hospital  was  41  days  (ranging  from  8  to  96
ays) [21].  Higher  viral  load  determination  in  the
pper respiratory  tract  has  been  associated  with
ncreased  severity  of  the  disease,  admission  to  the
CU and  increased  mortality  [34].
reatment
ince  there  are  no  speciﬁc  treatments  that  have
roven  to  be  effective  for  MERS-CoV,  case  man-
gement has  largely  relied  on  organ-supportive
herapy  and  prevention  of  complications.  While
o-infections  can  be  treated  with  speciﬁc  antimi-
robial  and  antiviral  medications,  potential  agents
o treat  MERS-CoV  infection  have  been  derived
rom experience  with  non-inﬂuenza  respiratory
iral infections,  including  severe  acute  respiratory
yndrome (SARS).  Case  studies  have  reported  on
he outcomes  of  patients  treated  with  oral  ribavi-
in and  interferon  a2b.  However,  such  studies  are
t a high  risk  of selection  bias  and  confounding
y indication  because  the  inclusion  of  patients  has
argely depended  on  the  severity  of  the  illness.
uch non-randomized  allocations  cannot  separateal  spectrum  of  the  Middle  East  respiratory  syndrome
://dx.doi.org/10.1016/j.jiph.2016.04.008
he inﬂuence  of  many  other  potentially  confounding
onditions and  co-interventions.  Previous  studies
ay also  have  been  affected  by  the  immortal  time
ias, as  the  patients  needed  to  remain  alive  long
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nough  to  receive  a  particular  therapy.  All  of  these
orms of  bias  and  confounding  variables  preclude
ny valid  estimation  of  the  true  treatment  effect.
Currently, a  phase  II,  open-label,  single  group
ssignment, safety/efﬁcacy  study  of  convalescent
lasma therapy  (plasma  derived  from  survivors  of
ERS-CoV  infection)  is underway  at  the  King  Abdul-
ah International  Medical  Research  Center  in  Saudi
rabia,  and  it  is  expected  to  be  completed  by  June
017 [36].  A  recombinant  modiﬁed  vaccinia  virus
nkara vaccine  expressing  the  full-length  MERS-CoV
pike  glycoprotein  has  been  developed  for  preven-
ative  purposes,  and  it  has  been  endorsed  by  the
erman  Center  for  Infection  Research  (DIFZ)  for
hase I clinical  trials  in  humans.  However,  there
s not  yet  any  human  data  regarding  the  potential
ffectiveness of  the  vaccine  [37,38].
Little is  known  about  the  long-term  outcomes
f patients  with  MERS-CoV.  However,  according  to
he largest  cohort  of  conﬁrmed  MERS-CoV  patients
n = 14)  who  were  intubated  and  received  invasive
echanical ventilation,  those  (n  = 5)  who  recovered
rom  the  acute  infection  and  its  complications  have
urvived  to  the  one  year  follow-up  period  [39].
onclusion
n  the  short  time  since  MERS-CoV  has  been
iscovered, signiﬁcant  progress  has  been  made
n understanding  the  epidemiology,  pathophy-
iology, clinical  manifestations,  and  potential
reatment options.  However,  many  important  ques-
ions remain.  Although  exposure  to  camels  has  been
mplicated  in  human  MERS-CoV  cases,  all  poten-
ial animal  reservoirs  have  not  yet  been  identiﬁed.
ffective treatments  and  vaccines  have  also  yet
o be  developed.  Because  of  the  sporadic  nature
f MERS-CoV  outbreaks,  a  collaborative  research
ffort across  the  most  affected  countries  will  be
ecessary  to  better  assess  the  potential  animal
eservoirs, epidemiology,  risk  factors,  and  trans-
ission  of  MERS-CoV  to  develop  controlled  and
deally blinded  treatment  evaluations.  Research
rotocols and  data  collection  tools  should  be  pre-
ared,  vetted,  approved,  and  pre-positioned  across
he Middle  East  and  elsewhere  to  facilitate  the
imely implementation  of  research  activities  and
lose many  of  the  remaining  knowledge  gaps.
unding
o  funding  sources.Please  cite  this  article  in  press  as:  Senga  M,  et  al.  Clinic
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